Derrick Rossi
Co-founder 2010Background
Derrick Rossi was a stem cell biologist at Harvard Medical School and the Harvard Stem Cell Institute when he discovered that modified mRNA could reprogram adult cells into induced pluripotent stem cells without the genetic modification risks of viral vectors. This 2010 breakthrough, published in Cell Stem Cell, formed the scientific foundation of Moderna. Rossi had previously trained at Stanford University and the University of Helsinki, and his work built on the foundational mRNA research of Katalin Karikó and Drew Weissman at the University of Pennsylvania. Rossi's decision to pursue commercialization of mRNA technology rather than pure academic research was driven by the realization that the technology could address a vast range of diseases beyond stem cell reprogramming. The founder's contributions to Moderna exemplify the intersection of academic research, venture capital, and entrepreneurial vision that drives biotechnology innovation.
Role at Moderna, Inc.
Moderna possesses a technical, engineered founding story, rooted entirely in the venture capital ecosystem of Cambridge, Massachusetts, and driven by a brilliant, intensely aggressive conviction in an unproven biological theory. The company was founded in 2010 by a prestigious group of scientists and venture capitalists, heavily driven by Noubar Afeyan (founder of Flagship Pioneering), Robert Langer (the legendary MIT professor), and Derrick Rossi (a brilliant stem cell biologist). Rossi possessed a 'eureka' moment; he figured out a complex method to modify messenger RNA (mRNA) and insert it into living cells to heavily instruct them to produce specific proteins, without triggering a toxic immune response. Afeyan immediately recognized the revolutionary potential: if they could harness this, they wouldn't just build a new drug; they would build a programmable 'software platform' for the human body. They founded the company, originally named 'ModeRNA Therapeutics'. Their foundational masterstroke was recruiting Stéphane Bancel, an aggressive, intensely demanding French executive, as CEO in 2011. Bancel instituted an intense, culture of secrecy and aggressive fundraising, raising billions of dollars before ever having a single successful clinical trial. For a decade, critics heavily derided the company as arrogant 'vaporware.' However, their world-changing validation occurred in 2020. Utilizing their advanced, programmable mRNA platform, they designed their effective COVID-19 vaccine in just two days after receiving the genetic sequence, silencing their critics and transforming a controversial biotech startup into the savior of the global economy.